Key Drivers
- Strong margins
- Weak cash conversion
- Leverage risk
AIAI Summary
GMAB is shifting from a royalty-dependent story to a profitable commercial growth platform with multiple late-stage catalysts, but the stock's real rerating path depends on sustained revenue acceleration and clean cash conversion while investors navigate binary Phase 3 readouts in late 2026–early 2027.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Weak cash conversion
- •Leverage risk
GMAB remains a profitable, high-margin business with solid liquidity, but weak quarterly cash conversion, meaningful leverage, and an intangibles-heavy balance sheet temper the outlook.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Near resistance
- •Quick run-up
GMAB is in a constructive short-term uptrend over the last month, with higher lows and prices near the top of the recent range, but it should hold the $29.0 area and break above $31.94 to confirm further upside.
Sharp dip on 2026-08-06 from the low $30s to about $29.83 before recovering
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Guidance raise
- •Pipeline expansion
Genmab delivered strong H1 2026 growth, raised full-year guidance on DARZALEX/EPKINLY strength, and continued advancing multiple late-stage oncology programs.
The news is supportive for the stock, reinforcing confidence in Genmab's commercial momentum and late-stage growth outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings